ANI Pharmaceuticals (NASDAQ:ANIP) Updates FY25 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share guidance of $6.12-6.49 for the period, compared to the consensus earnings per share estimate of $5.56. The company issued revenue guidance of $756-776 million, compared to the consensus revenue estimate of $724.88 million.

ANI Pharmaceuticals Trading Up 13.4 %

NASDAQ ANIP opened at $61.89 on Friday. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company’s 50 day moving average price is $57.23 and its 200 day moving average price is $58.13. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -112.53 and a beta of 0.74.

Analyst Ratings Changes

Several research analysts recently commented on ANIP shares. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $77.71.

Insider Transactions at ANI Pharmaceuticals

In other news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,300 shares of company stock valued at $584,009. 12.70% of the stock is currently owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.